Risk Factors and Preventive Measures for Hepatocellular carcinoma (HCC) 울산의대울산대병원소화기내과박능화

Size: px
Start display at page:

Download "Risk Factors and Preventive Measures for Hepatocellular carcinoma (HCC) 울산의대울산대병원소화기내과박능화"

Transcription

1 Risk Factors and Preventive Measures for Hepatocellular carcinoma (HCC) 울산의대울산대병원소화기내과박능화

2 Risk factors for HCC development (I) Environmental factors Infectious HBV HCV HDV Alimentary Alcohol Diet High calory intake Toxic Aflatoxin B1 Steroids Anabolics Chronic inflammation HCC Liver cirrhosis Host/genetic factors General Gender Ethnlclty Metabolic defect Hemochromatosis NAFLD Obesity Alpha-1-antitrypsin deficiency Autoimmune hepatitis Cryptogenic cirrhosis Dig Dis 2009;27:80 92

3 Natural history of chronic liver disease * Incidence per 100 person years

4 Risk factors for HCC development (II) Dig Dis 2009;27:80 92

5 The etiology of HCC in Korea HBV HCV Alcohol Autoimmune PBC Wilson Cryptogenic Miscellaneous 14.5% 0.4% 66.6% 9.4% 0.2% 0.2% 4.2% 4.5% ; > 80% NAFLD 환자 20,964 명 (%) Lee CH, 2001

6 Annual incidence rates of HCC according to underlying disease Dig Dis 2009;27:80 92

7 Chronic hepatitis B EM Schematic structure The story began back in Genome and proteins when Baruch Blumberg discovered the Australia antigen in serum

8 Natural history of hepatitis B recovery perinatal infection childhood infection adult infection recovery 10~90% 30% < 5% Chronic infection Mild/moderate/severe Chronic hepatitis ~ 1 * Inactive carrier state 2~10* ~ 4 * Cirrhosis 2~8* ~ 0.1 * ~ 3 * decompensation Death/transplantation HCC * Incidence per 100 person years

9 Current concepts of HBV-associated hepatocarcinognesis

10 Association of HBV with HCC (I) High prevalence of chronic HBV infection = high incidence and mortality of HCC

11 Risk factors associated with HCC Association of HBV with HCC (II) In an 8-year follow-up of the 90,000-Person prospective cohort study in Haimen City, China Cancer Epidemiol Biomarkers Prev 2002;11:

12 Factors in increasing risk of HBV-HCC Viral factors: HBV replication, genotype, longer duration of infection, co-infection with HCV, HIV or HDV Clinical factor: cirrhosis Host factors: male, older age, Asian, family Hx of HCC Environmental factors: aflatoxin B1, alcohol, smoking

13 The incidence rates of HCC in subjects with chronic HBV infection Journal of Hepatology 48 (2008)

14 Virus factors for progression of HBV-HCC HBeAg positivity and the risk of HCC NEJM 2002;347:168-74

15 Association between viral replication and HBV-HCC REVEAL (Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer): prospective, multicenter, observational cohort study : 7 Taiwanese townships Individuals aged years eligible (N = 89,293) HCC-free individuals enrolled (n = 23,820) Excluded if cirrhotic within 6 months Cirrhosis Analysis (n = 3774) 2004: 42,115 PYs follow-up 395 cirrhotic patients (10.5%) Gastroenterology 2006;130: HCC Analysis HBsAg+ with BL HBV DNA (n = 3851) 2004: 43,993 PYs follow-up 176 HCC patients (4.5%) JAMA 2006;295:65-73

16 REVEAL: Baseline HBV DNA and Liver Disease Progression at natural history cohort REVEAL (Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer): prospective, multicenter, observational cohort study HBV DNA HCC : LC: JAMA 2006;295:65-73 Gastroenterology 2006; 130: HCC: Gastroenterology 2011; 142: ALT

17 Risk factors associated with HCC JAMA 2006;295:65-73

18 간세포암종누적발생률 (%) Cumulative incidence of HCC by serum HBV DNA at entry Multivariate-adjusted Relative Risk 환자수 = 3,653 (*HBeAg negative N=3,088) Baseline HBV DNA 10 6 (copies/ml) RR* < p< < <10 4 < 추적년수 *Multiple Cox Proportional Hazard Regression Analyses JAMA 2006;295:65-73

19 HCC by serum HBV DNA levels at entry and at last f/u JAMA 2006;295:65-73

20 Nine groups of long-term changes in HBV DNA over follow-up Gastroenterology 2011;142:

21 Risk factors of HCC for group of long-term changes of HBV DNA, and ALT Gastroenterology 2011;142:

22 REVEAL: Summary of Key Conclusions Higher HBV DNA levels at baseline associated with an increased risk of cirrhosis and HCC. Continued viremia associated with an increased risk for HCC. For participants with the same HBV DNA levels at enrollment, greater decreases in serum HBV DNA levels during follow-up were associated with lower risk of HCC.

23 Associations between HBV genotype and mutants and the risk of HCC J Natl Cancer Inst 2008;100:

24 Carriers of inactive HBV are still at risk for HCC GASTROENTEROLOGY 2010;138:

25 Association between occult HBV infection and the risk of HCC: a meta-analysis (II) Comparing HCC risk in occult HBV and HCV-co-infected cases with that in those with HCV mono-infection Liver Int 2012; 32:

26 Association between occult HBV infection and the risk of HCC (I) The risk of HCC risk individuals with occult HBV infection with that in those without infection Liver Int 2012; 32:

27 Family History of Liver Cancer and HCC HEPATOLOGY 2012;55:

28 The combined effect of HBV and HCV infections in causing HCC British Journal of Cancer 2005; 92:

29 Cigarette smoking, alcohol drinking, Hepatitis B, and risk for HCC in Korea J Natl Cancer Inst 2004;96:1851 5]

30 Prevention of HCC in patients with HBV infection Primary Prevention of HCC: vaccination, including passive immunization, particularly of infants whose mothers have HBeAg Secondary Prevention of HCC: 1) control of viral replication with appropriate antiviral therapy 2) detect HCC at an early stage : periodic surveillance using ultrasonography and serum AFP Tertiary Prevention of HCC : to prevent tumor recurrence after resection J Natl Cancer Inst 2004;96:1851 5]

31 Hepatitis B vaccination program: historic overview in Korea 1982 First home-made plasma-derived hepatitis B vaccine in Korea 1983 HBV vaccine launched in Korea 1985 Newborn infants whose mothers were HBsAg carriers in Korea 1988 HBV vaccination for school age children in Korea 1991 Listed on vaccination guideline for children in Korea 1995 Universal HBV vaccination for infants in Korea 2002 HBV vertical transmission prevention program

32 Changes in HBsAg positivity among children for 25 years HBsAg positivity (%) % 10 9 Primary prevention (I) <10 10~19 Age(years)

33 Changes in HBsAg positivity by age group for 25 years HBsAg positivity (%) Primary prevention (I) % Kor J Gastroenterol 1999;33: A National Health and Nutrition Survey (NHNS)

34 Changes in HBsAg positivity by age group for 25 years Primary prevention (I)

35 Universal HBV vaccination in Taiwan and the incidence of HCC in children Primary prevention (II) N Engl J Med 1997;336:1855-9

36 Hepatitis B vaccination and risk of HCC among male adults Primary prevention (I) Serologlcal profiles and vacclnation status HBsAg(-) and Anti-HBs(-) Incidence rate of HCC Relative risk of HCC (95% CI) Non-vaccinee (The unvaccinated and uninfected group) Vaccinee (The vaccinated group) ( ) HBsAg(-) and Anti-HBs(+) (The unvaccinated and infected group) ( ) HBsAg(+) and Anti-HBs(-) (The chronically infected group) ( ) International Journal of Epidemiology 1998:27:

37 Decreased Incidence of HCC in Hepatitis B Vaccinees: A 20-Year Follow-up Study Primary prevention (II) J Natl Cancer Inst 2009;101:

38 Management of HBV related liver disease Secondary Prevention of HCC (I) 30.8% 19.6% 17.0% 13.3% 4.5% 7.0% 3 Cumulative appearance rates of hepatocellular carcinoma (HCC) in the interferon (IFN) therapy group and the untreated group (product-limit method). Cancer 1998;82:

39 Effects of IFN on development of HCC groups: a meta-analysis of randomized controlled trials (I) In HBV-infected patients Aliment Pharmacol Ther 2008;28:

40 Effects of IFN on development of HCC groups: a meta-analysis of randomized controlled trials (II) In HBV-infected patients Journal of Viral Hepatitis 2009; 16:

41 Effects of Lamivudine on development of HCC The Cirrhosis and Lamivudine Monotherapy (CALM) study 16(7.8%) 17(3.4%) NEJM 2004;351:

42 Cumulative incidence of HCC during Lamivudine Therapy 656 HBe Ag(-) (MVR, maintained virological response ; VBT, virological breakthrough) Hepatology 2004;40:

43 Cumulative rates of development of cirrhosis or HCC 142 HBe Ag(+) for long-term LAM (mean 89.9 months) 124 HBe Ag(+) control Antivir Ther 2007;12:

44 CHB related HCC with Lamivudine J Hepatology 2010;53:

45 HBe Ag(-) liver cirrhosis with Lamivudine in Greece Gut 2011;60:

46 The incidence of LTCs in patients without drugresistance between NA treatment and no treatment: a meta-analysis Virology J 2011;8:72-83

47 The incidence of LTCs in patients with drugresistance between NA treatment and no treatment: a meta-analysis Virology J 2011;8:72-83

48 The incidence of LTCs between patients with and without drug-resistance among the NA treatment groups: a meta-analysis Virology J 2011;8:72-83

49 The incidence of LTCs in HBeAg-negative patients between NA treatment and no treatment: a metaanalysis Virology J 2011;8:72-83

50 The incidence of LTCs in HBeAg-positive patients between NA treatment and no treatment: a metaanalysis Virology J 2011;8:72-83

51 The incidence of LTCs in patients with preexisting cirrhosis between NA treatment and no treatment: a meta-analysis Virology J 2011;8:72-83

52 The incidence of LTCs in patients without preexisting cirrhosis between NA treatment and no treatment: a meta-analysis Virology J 2011;8:72-83

53 The incidence of LTCs between patients with and without pre-existing compensated cirrhosis among the NA treatment groups: a meta-analysis Virology J 2011;8:72-83

54 Management of HBV related liver disease Goal in HBV related liver disease : suppress HBV replication reduce hepatitis activity prevent hepatic decompensation prevent HCC development prolong survival

55 The secondary prevention of HCC is detecting HCC at an earlier stage Secondary Prevention of HCC (II) J Cancer Res Clin Oncol 2004; 130:

56 Tertiary Prevention of HCC in Patients with HBV Infection Cumulative HCC recurrence related to the initial viral load at the time of tumor resection Am J Gastroenterol 2008;103:

57 Tertiary Prevention of HCC in Patients with HBV Infection Persistent hepatitis B viral replication increases the recurrence of HCC after curative resection British Journal of Surgery 2009; 96:

58 Tertiary Prevention of HCC in Patients with HBV Infection Interferon after curative treatment of HCC in patients with viral hepatitis British Journal of Surgery 2009; 96:

59 Tertiary Prevention of HCC in Patients with HBV Infection Interferon after curative treatment of HCC in patients with viral hepatitis British Journal of Surgery 2009; 96:

60 HCV-induced hepatocarcinogenesis Journal of Hepatology 2009; 51:

61 Association HCV infection and the risk of HCC Host and environmental factors in determining progression of HCC: older age at diagnosis, duration of infection, male sex, severity of liver disease at presentation, co-morbidities such as porphyria cutanea tarda, heavy alcohol intake, diabetes mellitus, steatosis, obesity and co-infections, especially with HBV. Int J Cancer 2004; 112:

62 Effects of IFN on development of HCC groups: a meta-analysis of randomized controlled trials In HCV-infected patients Int J Cancer 2011;129:

63 Proposed model of liver carcinogenesis by alcohol intake CYP2E1 ROS Lipid peroxidation MDA 4HNE Alcohol (CH 3 CH 2 OH) Acetaldehyde (CH 3 CHO) Protein + DNA Adducts ADH Acetate (CH 3 COO) Krebs Cycle ALDH Transformation, Altered cell signaling. Foci Development? HCC? Am J Epidemiol 2002;155:

64 Effects of alcohol on development and progression of HCC Am J Epidemiol 2002;155:

65 Effects of alcohol on development and progression of HCC Am J Epidemiol 2002;155:323 31

66 The association between obesity and HCC British Journal of Cancer 2007; 97:

67 The Association between Diabetes and HCC Int J Cancer 2012; 130:

68 Fasting Serum Glucose Level and Cancer Risk in Korean Men and Women JAMA. 2005;293:

69 Expanding the Natural History of Nonalcoholic Steatohepatitis: From Cryptogenic Cirrhosis to HCC GASTROENTEROLOGY 2002;123:

70 Coffee consumption and risk of HCC: A Meta-Analysis The mechanisms by which coffee reduces the risk of liver disease: Caffeine, cafestol and ditrepens - similar to enzymes involved in carcinogen detoxification. HEPATOLOGY 2007;46:

71 Coffee consumption and risk of HCC: A Meta-Analysis RRs of HCC for coffee drinkers versus non-drinkers among carriers of HBV and/or HCV or other chronic liver diseases HEPATOLOGY 2007;46:

72 Other risk factors for HCC Autoimmune hepatitis Hemochromatosis α1 -Antitrypsin Deficiency Wison s disease Alagille syndrome, Hypercitrullinemia, Glycogenosis type 1 Oral contraceptives, Anabolic steroids Tobacco Smoking Aflatoxin B1 Diet and Toxic Agents :HCC risk - linoleic acid (OR 0.35, 95% CI ) - b-carotene (OR 0.48, 95% CI ) - high intakes of milk and yoghurt, eggs, white meats and fruit - diet containing tributyrin Host Genetic Factors - polymorphism

73 Prevention of HCC HBV vaccination Perinatal hepatitis B immunoglobulin Safe sex Treatment Of hepatitis C Primary prevention (Prevention of viral hepatitis) Prevent Needle sharing Antiviral therapy for HBV Avoid excessive alcohol Secondary prevention (Prevention of HCC in susceptible patients Antiviral therapy forhcv Safe food storage to prevent aflatoxin Regular HCC surveillance by ultrasound and/ or alpha fetoprotein Early HCC detection Early curative treatment of HCC

74

Viral hepatitis and Hepatocellular Carcinoma

Viral hepatitis and Hepatocellular Carcinoma Viral hepatitis and Hepatocellular Carcinoma Hashem B. El-Serag, MD, MPH Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Houston VA & Baylor College of Medicine Houston, TX Outline

More information

Viral Hepatitis The Preventive Potential of Antiviral Therapy. Thomas Berg

Viral Hepatitis The Preventive Potential of Antiviral Therapy. Thomas Berg Viral Hepatitis The Preventive Potential of Antiviral Therapy Thomas Berg Therapeutic and preventive strategies in patients with hepatitis virus infection Treatment of acute infection Treatment of chronic

More information

Hepatocellular Carcinoma: Can We Slow the Rising Incidence?

Hepatocellular Carcinoma: Can We Slow the Rising Incidence? Hepatocellular Carcinoma: Can We Slow the Rising Incidence? K.Rajender Reddy M.D. Professor of Medicine Director of Hepatology Medical Director of Liver Transplantation University of Pennsylvania Outline

More information

HEPATOCELLULAR CARCINOMA: SCREENING, DIAGNOSIS, AND TREATMENT

HEPATOCELLULAR CARCINOMA: SCREENING, DIAGNOSIS, AND TREATMENT HEPATOCELLULAR CARCINOMA: SCREENING, DIAGNOSIS, AND TREATMENT INTRODUCTION: Hepatocellular carcinoma (HCC): Fifth most common cancer worldwide Third most common cause of cancer mortality In Egypt: 2.3%

More information

Serum Hepatitis B Surface Antigen Levels Help Predict Disease Progression in Patients With Low Hepatitis B Virus Loads. Hepatology Feb 2013

Serum Hepatitis B Surface Antigen Levels Help Predict Disease Progression in Patients With Low Hepatitis B Virus Loads. Hepatology Feb 2013 Serum Hepatitis B Surface Antigen Levels Help Predict Disease Progression in Patients With Low Hepatitis B Virus Loads Hepatology Feb 2013 Hepatitis B Surface Antigen HBsAg is the glycosylated envelope

More information

Management of Chronic Hepatitis B in Asian Americans

Management of Chronic Hepatitis B in Asian Americans Management of Chronic Hepatitis B in Asian Americans Myron J Tong; UCLA, CA Calvin Q. Pan; Mount Sinai, NY Hie-Won Hann; Thomas Jefferson, PA Kris V. Kowdley; Virginia Mason, WA Steven Huy B Han; UCLA,

More information

HCC Prevention. Jee-Fu Huang. Kaohsiung Municipal Hsiao-Kang Hospital, KMUH Kaohsiung (Takao), Taiwan. TCC, HCC Prevention, 26 Nov, 2011

HCC Prevention. Jee-Fu Huang. Kaohsiung Municipal Hsiao-Kang Hospital, KMUH Kaohsiung (Takao), Taiwan. TCC, HCC Prevention, 26 Nov, 2011 HCC Prevention Jee-Fu Huang Kaohsiung Municipal Hsiao-Kang Hospital, KMUH Kaohsiung (Takao), Taiwan TCC, HCC Prevention, 26 Nov, 2011 1 Outline Pathogenic and Risk Factors HBV HCV Primary Secondary Primary

More information

Viral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital

Viral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital Viral Hepatitis Dr Melissa Haines Gastroenterologist Waikato Hospital Viral Hepatitis HAV HBV HCV HDV HEV Other viral: CMV, EBV, HSV Unknown Hepatitis A Hepatitis A Transmitted via the faecal-oral route

More information

What have we learned from HBV clinical cohorts?

What have we learned from HBV clinical cohorts? PHC 2015: Hepatitis B What have we learned from HBV clinical cohorts? Jia-Horng Kao MD, Ph D Graduate Institute of Clinical Medicine, Hepatitis Research Center, Department of Internal Medicine, National

More information

Natural History of Chronic Hepatitis B

Natural History of Chronic Hepatitis B Natural History of Chronic Hepatitis B Anna SF Lok, MD Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research University of Michigan Ann Arbor,

More information

Cornerstones of Hepatitis B: Past, Present and Future

Cornerstones of Hepatitis B: Past, Present and Future Cornerstones of Hepatitis B: Past, Present and Future Professor Man-Fung Yuen Queen Mary Hospital The University of Hong Kong Hong Kong 1 Outline Past Natural history studies Development of HBV-related

More information

Does Viral Cure Prevent HCC Development

Does Viral Cure Prevent HCC Development Does Viral Cure Prevent HCC Development Prof. Henry LY Chan Head, Division of Gastroenterology and Hepatology Director, Institute of Digestive Disease Director, Center for Liver Health Assistant Dean,

More information

The Chronic Liver Disease Foundation (CLDF) and the International Coalition of Hepatology Education Providers (IC-HEP) present:

The Chronic Liver Disease Foundation (CLDF) and the International Coalition of Hepatology Education Providers (IC-HEP) present: The Chronic Liver Disease Foundation (CLDF) and the International Coalition of Hepatology Education Providers (IC-HEP) present: Certified by: Provided by: Endorsed by: Hepatocellular Carcinoma HCC: Age

More information

Screening for HCCwho,

Screening for HCCwho, Screening for HCCwho, how and how often? Catherine Stedman Associate Professor of Medicine, University of Otago, Christchurch Gastroenterology Department, Christchurch Hospital HCC Global Epidemiology

More information

Chronic Hepatitis B Infection

Chronic Hepatitis B Infection Chronic Hepatitis B Infection Mohssen Nassiri Toosi, MD Imam Khomeinin Hospital Tehran University of Medical Sciences Chronic Hepatitis B Infection Virus : HBs Ag Positive Host Liver Health Chronic Hepatitis

More information

NH2 N N N O N O O P O O O O O

NH2 N N N O N O O P O O O O O N N NH 2 N N O O P O O O O O O James Watson and Francis Crick Double Helix 1953 Baruch Blumberg, MD, PhD 1925-2011 Australia Antigen 1965 Hepatitis B Virus (HBV) Hepadnaviridae member that primarily infects

More information

Hepatitis B. What's the impact on the risk? Dr Himanshu Bhatia, Asia Chief Medical Officer ALUCA, Brisbane, Sept 2013

Hepatitis B. What's the impact on the risk? Dr Himanshu Bhatia, Asia Chief Medical Officer ALUCA, Brisbane, Sept 2013 Hepatitis B What's the impact on the risk? Dr Himanshu Bhatia, Asia Chief Medical Officer ALUCA, Brisbane, Sept 2013 Some quick facts about Hepatitis B Worldwide: 350-400 Million are chronic infections

More information

The Impact of HBV Therapy on Fibrosis and Cirrhosis

The Impact of HBV Therapy on Fibrosis and Cirrhosis The Impact of HBV Therapy on Fibrosis and Cirrhosis Jordan J. Feld, MD, MPH Associate Professor of Medicine University of Toronto Hepatologist Toronto Centre for Liver Disease Sandra Rotman Centre for

More information

Clinical Management of Hepatitis B WAN-CHENG CHOW DEPARTMENT OF GASTROENTEROLOGY & HEPATOLOGY SINGAPORE GENERAL HOSPITAL

Clinical Management of Hepatitis B WAN-CHENG CHOW DEPARTMENT OF GASTROENTEROLOGY & HEPATOLOGY SINGAPORE GENERAL HOSPITAL Clinical Management of Hepatitis B WAN-CHENG CHOW DEPARTMENT OF GASTROENTEROLOGY & HEPATOLOGY SINGAPORE GENERAL HOSPITAL The World Health Organisation recent initiatives on HBV infection Launching of the

More information

Chronic Hepatitis B: management update.

Chronic Hepatitis B: management update. Chronic Hepatitis B: management update. E.O.Ogutu Department of clinical medicine & therapeutics, University of Nairobi. Physicians meeting,kisumu 2011. Background epidemiology Chronic hepatitis B (CHB)

More information

Hepatitis B Update. Jorge L. Herrera, M.D. University of South Alabama Mobile, AL. Gastroenterology

Hepatitis B Update. Jorge L. Herrera, M.D. University of South Alabama Mobile, AL. Gastroenterology Hepatitis B Update Jorge L. Herrera, M.D. University of South Alabama Mobile, AL Deciding Who to Treat Is hepatitis B a viral disease or a liver disease? Importance of HBV-DNA Levels in the Natural History

More information

Jose D Sollano, MD Professor of Medicine University of Santo Tomas Manila, Philippines. University of Santo Tomas

Jose D Sollano, MD Professor of Medicine University of Santo Tomas Manila, Philippines. University of Santo Tomas Jose D Sollano, MD Professor of Medicine Manila, Philippines International Variation in Age-Standardized Liver Cancer Incidence Rates in Both Sexes, 2008 Global Age-Standardized Liver Cancer Incidence

More information

Tumor incidence varies significantly, depending on geographical location.

Tumor incidence varies significantly, depending on geographical location. Hepatocellular carcinoma is the 5 th most common malignancy worldwide with male-to-female ratio 5:1 in Asia 2:1 in the United States Tumor incidence varies significantly, depending on geographical location.

More information

Natural History of HBV Infection

Natural History of HBV Infection Natural History of HBV Infection Joseph JY Sung MD PhD Institute of Digestive Disease Department of Medicine & Therapeutics Prince of Wales Hospital The Chinese University of Hong Kong HBV Infection 2

More information

End Stage Liver Disease & Disease Specific Indications for Liver Transplant. Susan Kang, RN, MSN, ANP-BC

End Stage Liver Disease & Disease Specific Indications for Liver Transplant. Susan Kang, RN, MSN, ANP-BC End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP-BC Introduction (https://www.srtr.org) What does the liver do? STORAGE METABOLIC DETOXIFICATION SYNTHETIC

More information

End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC

End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC Introduction (https://www.srtr.org) 1 What does the liver do? STORAGE METABOLIC DETOXIFICATION SYNTHETIC

More information

Worldwide Causes of HCC

Worldwide Causes of HCC Approach to HCV Treatment in Patients with HCC JORGE L. HERRERA, MD, MACG UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE Worldwide Causes of HCC 60% 50% 40% 54% 30% 20% 10% 31% 15% 0% Hepatitis B Hepatitis

More information

The impact of the treatment of HCV in developing Hepatocellular Carcinoma

The impact of the treatment of HCV in developing Hepatocellular Carcinoma The impact of the treatment of HCV in developing Hepatocellular Carcinoma Paul Y Kwo, MD Professor of Medicine Medical Director, Liver Transplantation Gastroenterology/Hepatology Division Indiana University

More information

Liver Cancer Causes, Risk Factors, and Prevention

Liver Cancer Causes, Risk Factors, and Prevention Liver Cancer Causes, Risk Factors, and Prevention Risk Factors A risk factor is anything that affects your chance of getting a disease such as cancer. Learn more about the risk factors for liver cancer.

More information

Should we treat hepatitis B positive pregnant women to prevent mother to child transmission?

Should we treat hepatitis B positive pregnant women to prevent mother to child transmission? Should we treat hepatitis B positive pregnant women to prevent mother to child transmission? Daniel Shouval Liver Unit Hadassah-Hebrew University Hospital Jerusalem, Israel VHPB Vienna June 1-2, 2017 Background

More information

Treatment of chronic hepatitis B 2013 update

Treatment of chronic hepatitis B 2013 update 22 February 213 Treatment of chronic hepatitis B 213 update Pietro Lampertico 1st Gastroenterology Unit Fondazione IRCCS Cà Granda - Ospedale Maggiore Policlinico Università di Milano EASL 212 Clinical

More information

Dr David Rowbotham NHS. The Leeds Teaching Hospitals. NHS Trust

Dr David Rowbotham NHS. The Leeds Teaching Hospitals. NHS Trust Dr David Rowbotham The Leeds Teaching Hospitals NHS Trust NHS Nurses Update June 2010 Chronic Hepatitis HBV / HCV David Rowbotham Clinical Director & Consultant Gastroenterologist Dept of Gastroenterology

More information

Worldwide Causes of HCC

Worldwide Causes of HCC Approach to HCV Treatment in Patients with HCC Mark W. Russo, MD, MPH, FACG Carolinas HealthCare System Charlotte Worldwide Causes of HCC 60% 50% 40% 30% 20% 10% 0% 54% 31% 15% Hepatitis B Hepatitis C

More information

Hepatitis B. ECHO November 29, Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University

Hepatitis B. ECHO November 29, Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University Hepatitis B ECHO November 29, 2017 Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University Disclosures Advisory board Gilead Comments The speaker Joseph

More information

Treatment as a form of liver cancer prevention The clinical efficacy and cost effectiveness of treatment across Asia

Treatment as a form of liver cancer prevention The clinical efficacy and cost effectiveness of treatment across Asia Treatment as a form of liver cancer prevention The clinical efficacy and cost effectiveness of treatment across Asia Prof. Henry LY Chan Head, Division of Gastroenterology and Hepatology Director, Institute

More information

Hepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain

Hepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &

More information

White Nights of Hepatology 2016

White Nights of Hepatology 2016 White Nights of Hepatology 2016 Saint Petersburg, 3 June 2016 Long-term treatment of Chronic hepatitis B - a key to HCC prevention Massimo Colombo Chairman Department of Liver, Kidney, Lung and Bone Marrow

More information

Hepatitis B. Epidemiology and Natural History and Implications for Treatment

Hepatitis B. Epidemiology and Natural History and Implications for Treatment Hepatitis B Epidemiology and Natural History and Implications for Treatment Norah Terrault, MD Professor of Medicine and Surgery Director, Viral Hepatitis Center University of California San Francisco

More information

HBV in HIV Forgotten but not Gone

HBV in HIV Forgotten but not Gone Activity Code FA376 HBV in HIV Forgotten but not Gone Richard K. Sterling, MD, MSc VCU Hepatology Professor of Medicine Chief, Section of Hepatology Virginia Commonwealth University Learning Objectives

More information

EAST LONDON INTEGRATED CARE

EAST LONDON INTEGRATED CARE CITY & HACKNEY ELIC EAST LONDON INTEGRATED CARE MANAGEMENT OF CHRONIC HEPATITIS B IN PRIMARY CARE Chronic Hepatitis B virus (HBV) is an important public health problem globally and a leading cause of liver

More information

Long-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance

Long-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance Long-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance Gi-Ae Kim, Han Chu Lee *, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim,

More information

Healthy Liver Cirrhosis

Healthy Liver Cirrhosis Gioacchino Angarano Clinica delle Malattie Infettive Università degli Studi di Foggia Healthy Liver Cirrhosis Storia naturale dell epatite HCVcorrelata in assenza di terapia Paestum 13-15 Maggio 24 The

More information

Journal of Antimicrobial Chemotherapy Advance Access published April 25, 2013

Journal of Antimicrobial Chemotherapy Advance Access published April 25, 2013 Journal of Antimicrobial Chemotherapy Advance Access published April 25, 213 J Antimicrob Chemother doi:1.193/jac/dkt147 Virological response to entecavir reduces the risk of liver disease progression

More information

Management of Hepatitis B - Information for primary care providers

Management of Hepatitis B - Information for primary care providers Management of Hepatitis B - Information for primary care providers July 2018 Chronic hepatitis B (CHB) is often a lifelong condition. Not everyone infected needs anti-viral therapy. This document outlines

More information

The Long Term Care Risk

The Long Term Care Risk Hepatitis C The Long Term Care Risk Objectives Basics of the disease Disease progression Comorbid factors Treatment Long term care risk Basics of Hepatitis C Caused by an RNA virus Clinical Course Acute

More information

WHEN HCV TREATMENT IS DEFERRED WV HEPC ECHO PROJECT

WHEN HCV TREATMENT IS DEFERRED WV HEPC ECHO PROJECT WHEN HCV TREATMENT IS DEFERRED WV HEPC ECHO PROJECT October 13, 2016 Reminder - treatment is recommended for all patients with chronic HCV infection Except short life expectancies that cannot be remediated

More information

Hepatitis B Virus. Taylor Page PharmD Candidate 2019 February 1, 2019

Hepatitis B Virus. Taylor Page PharmD Candidate 2019 February 1, 2019 Hepatitis B Virus Taylor Page PharmD Candidate 2019 February 1, 2019 Epidemiology 3218 cases of acute HBV reported in 2016 847,000 non-institutionalized persons living with chronic HBV in 2011-2012 Viral

More information

HBV Diagnosis and Treatment

HBV Diagnosis and Treatment HBV Diagnosis and Treatment Anna S. F. Lok, MD Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research University of Michigan Ann Arbor, MI, USA

More information

Hepatitis B virus infection. Chow Wan Cheng Dept of Gastroenterology & Hepatology Singapore General Hospital

Hepatitis B virus infection. Chow Wan Cheng Dept of Gastroenterology & Hepatology Singapore General Hospital Hepatitis B virus infection Chow Wan Cheng Dept of Gastroenterology & Hepatology Singapore General Hospital Chronic Hepatitis B - are we in the same situation as hepatitis C? Treatment of chronic hepatitis

More information

Whats new on HBsAg and other markers for HBV infection? Christoph Höner zu Siederdissen

Whats new on HBsAg and other markers for HBV infection? Christoph Höner zu Siederdissen Whats new on HBsAg and other markers for HBV infection? Christoph Höner zu Siederdissen Why diagnostic markers are important They are the basis for clinical decision makings treatment or no treatment?

More information

Need for long-term evaluation of therapy in Chronic Hepatitis B

Need for long-term evaluation of therapy in Chronic Hepatitis B Need for long-term evaluation of therapy in Chronic Hepatitis B VHPB meeting Budapest 18/03/2010 Solko Schalm & Mehlika Toy Licensed Therapy Chronic hepatitis B Drug Date of Efficacy Disease Clinical Mortality

More information

Viral Hepatitis Diagnosis and Management

Viral Hepatitis Diagnosis and Management Viral Hepatitis Diagnosis and Management CLINICAL BACKGROUND Viral hepatitis is a relatively common disease (25 per 100,000 individuals in the United States) caused by a diverse group of hepatotropic agents

More information

Are we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting?

Are we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting? Rajani Sharma, PGY1 Geriatrics CRC Project, 12/19/13 Are we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting? A. Study Purpose and Rationale Hepatocellular carcinoma

More information

Tenofovir as a drug of choice for the chronic hepatitis B treatment

Tenofovir as a drug of choice for the chronic hepatitis B treatment EASL endorsed conference White Nights of Hepatology 2013 Symposium Perspectives of chronic viral hepatitis B and C treatment June 6-7 Saint-Petersburg Tenofovir as a drug of choice for the chronic hepatitis

More information

An Update HBV Treatment

An Update HBV Treatment An Update HBV Treatment Epidemiology Natural history Treatment Daryl T.-Y. Lau, MD, MPH Associate Professor of Medicine Director of Translational Liver Research Division of Gastroenterology BIDMC, Harvard

More information

Steatosi epatica ed HCV

Steatosi epatica ed HCV Steatosi epatica ed HCV Malattie delle vie biliari ed Epatologia Rho, Auditorium Padri Oblati, 11 Novembre 2006 Piero L. Almasio Università di Palermo HISTOPATHOLOGY Steatosis and accelerated fibrogenesis:

More information

Viral Hepatitis And Liver Transplantation

Viral Hepatitis And Liver Transplantation Viral Hepatitis And Liver Transplantation Dr.Zeki KARASU Ege University Medical School Dep. Gastroenterology Hepatitis B 3-7 10 % HBV infection in liver transplant recipients, in western countries. 120

More information

Management of HBV in KidneyTransplanted Patients Dr.E.Nemati

Management of HBV in KidneyTransplanted Patients Dr.E.Nemati Management of HBV in KidneyTransplanted Patients Dr.E.Nemati Hepatitis B virus (HBV) infection Hepatitis B virus (HBV) infection confers a significantly negative impact on the clinical outcomes of kidney

More information

Hepatitis B in Africa: Epidemiology, Pathophysiology and Challenges

Hepatitis B in Africa: Epidemiology, Pathophysiology and Challenges Gilead-sponsored symposium at the 11th INTEREST Workshop 2017 Hepatitis B in Africa: Epidemiology, Pathophysiology and Challenges Ponsiano Ocama Department of Medicine Makerere University College of Health

More information

Hepatocellular Carcinoma Surveillance

Hepatocellular Carcinoma Surveillance Amit G. Singal, MD, MS Hepatocellular Carcinoma Surveillance Postgraduate Course: Challenges in Management of Common Liver Diseases 308 1 Patient Case 69 year-old otherwise healthy male with compensated

More information

CITY & HACKNEY ELIC EAST LONDON INTEGRATED CARE MANAGEMENT OF CHRONIC HEPATITIS B IN PRIMARY CARE

CITY & HACKNEY ELIC EAST LONDON INTEGRATED CARE MANAGEMENT OF CHRONIC HEPATITIS B IN PRIMARY CARE CITY & HACKNEY ELIC EAST LONDON INTEGRATED CARE MANAGEMENT OF CHRONIC HEPATITIS B IN PRIMARY CARE Chronic Hepatitis B virus (HBV) is an important public health problem globally and a leading cause of liver

More information

Who to Treat? Consider biopsy Treat. > 2 ULN Treat Treat Treat Treat CIRRHOTIC PATIENTS Compensated Treat HBV DNA detectable treat

Who to Treat? Consider biopsy Treat. > 2 ULN Treat Treat Treat Treat CIRRHOTIC PATIENTS Compensated Treat HBV DNA detectable treat Who to Treat? Parameter AASLD US Algorithm EASL APASL HBV DNA CRITERIA HBeAg+ >, IU/mL > 2, IU/mL > 2, IU/mL >, IU/mL HBeAg- > 2, IU/mL > 2, IU/mL > 2, IU/mL > 2, IU/mL ALT CRITERIA PNALT 1-2 ULN Monitor

More information

CURRENT TREATMENT. Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia

CURRENT TREATMENT. Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia CURRENT TREATMENT OF HBV Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia CHRONIC HBV INFECTION DEMOGRAPHICS IN THE USA Estimated

More information

Management of Patients with Chronic Hepatitis B: The Alaska Experience

Management of Patients with Chronic Hepatitis B: The Alaska Experience Management of Patients with Chronic Hepatitis B: The Alaska Experience Brian J McMahon, MACP, FAASLD Liver Disease and Hepatitis Program Alaska Native Tribal Health Consortium Disclosures I have no conflicts

More information

March 29, :15 PM 1:15 PM San Diego, CA Convention Center Ballroom 20D

March 29, :15 PM 1:15 PM San Diego, CA Convention Center Ballroom 20D March 29, 2017 12:15 PM 1:15 PM San Diego, CA Convention Center Ballroom 20D Provided by #IM2017 This lunch symposium is not part of the official Internal Medicine Meeting 2017 Education Program. #IM2017

More information

Hepatocellular Carcinoma: Epidemiology and Screening

Hepatocellular Carcinoma: Epidemiology and Screening Hepatocellular Carcinoma: Epidemiology and Screening W. Ray Kim, MD Professor and Chief Gastroenterology and Hepatology Stanford University School of Medicine Case A 67 year old Filipino-American woman

More information

Novedades en el tratamiento de la hepatitis B: noticias desde la EASL. Maria Buti Hospital Universitario Valle Hebrón Barcelona

Novedades en el tratamiento de la hepatitis B: noticias desde la EASL. Maria Buti Hospital Universitario Valle Hebrón Barcelona Novedades en el tratamiento de la hepatitis B: noticias desde la EASL Maria Buti Hospital Universitario Valle Hebrón Barcelona Milestones in CHB treatment Conventional IFN 1991 Lamivudine (LAM) 1998 Adefovir

More information

EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection

EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection European Association for the Study of the Liver Introduction Our understanding of the natural history of hepatitis B

More information

29th Viral Hepatitis Prevention Board Meeting

29th Viral Hepatitis Prevention Board Meeting 29th Viral Hepatitis Prevention Board Meeting Madrid, November 2006 Treatment of chronic hepatitis B José M. Sánchez-Tapias Liver Unit Hospital Clínic University of Barcelona Spain CHRONIC HBV INFECTION

More information

Hepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain

Hepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &

More information

Chronic Hepatitis B. What every GP should know. Prof Ed Gane NZ Liver Unit

Chronic Hepatitis B. What every GP should know. Prof Ed Gane NZ Liver Unit Chronic Hepatitis B What every GP should know Prof Ed Gane Z Liver Unit Case 1 55 Yr old Tonga male»well but dad died of liver cancer»lfts: ALT 85, GGT 60; ALP 75; bilirubin 12 What next? Case 1 55 Yr

More information

Hepatitis B: A Preventable Cause of Liver Cancer. Saira Khaderi MD, MPH Assistant Professor of Surgery Associate Director, Project ECHO June 17, 2016

Hepatitis B: A Preventable Cause of Liver Cancer. Saira Khaderi MD, MPH Assistant Professor of Surgery Associate Director, Project ECHO June 17, 2016 Hepatitis B: A Preventable Cause of Liver Cancer Saira Khaderi MD, MPH Assistant Professor of Surgery Associate Director, Project ECHO June 17, 2016 Overview Epidemiology HBV and cancer Screening, Diagnosis

More information

Basics of hepatitis B diagnostics. Dr Emma Page MRCP MD(Res) Locum Consultant Sexual Health & Virology

Basics of hepatitis B diagnostics. Dr Emma Page MRCP MD(Res) Locum Consultant Sexual Health & Virology Basics of hepatitis B diagnostics Dr Emma Page MRCP MD(Res) Locum Consultant Sexual Health & Virology Basics of hepatitis B diagnostics Background Epidemiology Morphology Life-cycle Diagnostic markers

More information

Hepatitis B screening and surveillance in primary care

Hepatitis B screening and surveillance in primary care Hepatitis B screening and surveillance in primary care Catherine Stedman Associate Professor of Medicine, University of Otago, Christchurch Gastroenterology Department, Christchurch Hospital Disclosures

More information

Community Dialogue Series The Lao Cultural Center. Hepatitis B in Asian Communities

Community Dialogue Series The Lao Cultural Center. Hepatitis B in Asian Communities Community Dialogue Series The Lao Cultural Center Hepatitis B in Asian Communities Jian-Min Yuan, MD, PhD Associate Professor Division of Epidemiology and Community Health School of Public Health & The

More information

Management of Decompensated Chronic Hepatitis B

Management of Decompensated Chronic Hepatitis B Management of Decompensated Chronic Hepatitis B Dr James YY Fung, FRACP, MD Department of Medicine The University of Hong Kong Liver Transplant Center Queen Mary Hospital State Key Laboratory for Liver

More information

Management of chronic hepatitis B : recent advance in the treatment of antiviral resistance

Management of chronic hepatitis B : recent advance in the treatment of antiviral resistance anagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance / 김강모 연수강좌 anagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance 김강모 울산대학교의과대학서울아산병원소화기내과

More information

HBV Therapy in Special Populations: Liver Cirrhosis

HBV Therapy in Special Populations: Liver Cirrhosis HBV Therapy in Special Populations: Liver Cirrhosis Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber- und Studienzentrum

More information

Hepatitis B Treatment Pearls. Agenda

Hepatitis B Treatment Pearls. Agenda Hepatitis B Treatment Pearls Fredric D. Gordon, MD Vice Chair Dept. of Transplantation and Hepatobiliary Diseases Lahey Hospital & Medical Center Associate Professor of Medicine Tufts Medical School Boston,

More information

The ABCs of Viral Hepatitis Diagnosis. Ila Singh, M.D., Ph.D. P & S Viral Hepatitis. Hepatitis A, B, C, D, E and G viruses

The ABCs of Viral Hepatitis Diagnosis. Ila Singh, M.D., Ph.D. P & S Viral Hepatitis. Hepatitis A, B, C, D, E and G viruses The ABCs of Viral Hepatitis Diagnosis Ila Singh, M.D., Ph.D. P & S 14-453 is132@columbia.edu Viral Hepatitis Hepatotropic viruses Hepatitis A, B, C, D, E and G viruses Generalized infection plus infection

More information

Choice of Oral Drug for Hepatitis B: Status Asokananda Konar

Choice of Oral Drug for Hepatitis B: Status Asokananda Konar Choice of Oral Drug for Hepatitis B: Status 2011 Asokananda Konar Chronic hepatitis B (CHB) is a global public health challenge with an estimated 350 to 400 million people with chronic HBV infection, despite

More information

Epidemiology of hepatitis B and D in Greece

Epidemiology of hepatitis B and D in Greece Epidemiology of hepatitis B and D in Greece George V. Papatheodoridis Assistant Professor in Medicine & Gastroenterology 2nd Department of Internal Medicine, Athens University Medical School, Hippokration

More information

Hepadnaviridae family (DNA) Numerous antigenic components Humans are only known host May retain infectivity for more than 7 days at room temperature

Hepadnaviridae family (DNA) Numerous antigenic components Humans are only known host May retain infectivity for more than 7 days at room temperature Hepatitis B Epidemic jaundice described by Hippocrates in 5th century BC Jaundice reported among recipients of human serum and yellow fever vaccines in 1930s and 1940s Australia antigen described in 1965

More information

Supplementary materials: Predictors of response to pegylated interferon in chronic hepatitis B: a

Supplementary materials: Predictors of response to pegylated interferon in chronic hepatitis B: a Supplementary materials: Predictors of response to pegylated interferon in chronic hepatitis B: a real-world hospital-based analysis Yin-Chen Wang 1, Sien-Sing Yang 2*, Chien-Wei Su 1, Yuan-Jen Wang 3,

More information

Update on HBV Treatment

Update on HBV Treatment Update on HBV Treatment Calvin Q. Pan MD, FAASLD, FACG, MACP Professor of Medicine Division of Gastroenterology and Hepatology Department of Medicine, NYU Langone Health New York University School of Medicine,

More information

GAZETTE COMMON GROUND. CHB: A significant and prevalent disease in the US and worldwide. Inside. Screening, diagnosis, and evaluation

GAZETTE COMMON GROUND. CHB: A significant and prevalent disease in the US and worldwide. Inside. Screening, diagnosis, and evaluation VOL III/III COMMON GROUND GAZETTE Inside CASE 1: Screening, diagnosis, and evaluation P. 1 CASE 2: Initiating treatment P. 4 CASE 3: Managing antiviral resistance P. 5 CASE 4: Achieving the maximum effect

More information

Hepatitis B infection

Hepatitis B infection Hepatitis B infection Kenneth Kabagambe Executive Director The National Organization for People Living with Hepatitis B (NOPLHB Uganda General introduction: Viral hepatitis in Uganda Viruses that affect

More information

Consensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition

Consensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition Consensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition Anna S. Lok, MD, DSc Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research

More information

IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS?

IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS? IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS? Dr. Sammy Saab David Geffen School of Medicine, Los Angeles, USA April 2018 DISCLAIMER Please note: The views

More information

EVALUATION OF ABNORMAL LIVER TESTS

EVALUATION OF ABNORMAL LIVER TESTS EVALUATION OF ABNORMAL LIVER TESTS MIA MANABAT DO PGY6 MOA 119 TH ANNUAL SPRING SCIENTIFIC CONVENTION MAY 19, 2018 EVALUATION OF ABNORMAL LIVER TESTS Review of liver enzymes vs liver function tests Clinical

More information

Clinical dilemmas in HBeAg-negative CHB

Clinical dilemmas in HBeAg-negative CHB Clinical dilemmas in HBeAg-negative CHB George V. Papatheodoridis Professor in Medicine & Gastroenterology Medical School of National & Kapodistrian University of Athens Director of Academic Department

More information

S401- Updates in the Treatments of Hepatitis B & C

S401- Updates in the Treatments of Hepatitis B & C S401- Updates in the Treatments of Hepatitis B & C Ruben Gonzalez-Vallina, MD Director of Gastroenterology Outpatient Initiatives Miami Children s Hospital Miami, Florida Disclosure of Relevant Relationship

More information

Viral hepatitis Blood Born hepatitis. Dr. MONA BADR Assistant Professor College of Medicine & KKUH

Viral hepatitis Blood Born hepatitis. Dr. MONA BADR Assistant Professor College of Medicine & KKUH Viral hepatitis Blood Born hepatitis Dr. MONA BADR Assistant Professor College of Medicine & KKUH Outline Introduction to hepatitis Characteristics of viral hepatitis Mode of transmission Markers of hepatitis

More information

What can the challenges we face? HBV: Long term NUC treatment

What can the challenges we face? HBV: Long term NUC treatment LUNCH WORKSHOP 30th January from 12:30 to 14:30 Future therapies for HBV and HDV: What can we expect? What can the challenges we face? HBV: Long term NUC treatment Massimo Levrero Cancer Research Center

More information

«Εκτίμηση κινδφνου ανάπτυξης ΗΚΚ σε ασθενείς με HCV λοίμωξη» Evaluation of HCC risk in HCV patients

«Εκτίμηση κινδφνου ανάπτυξης ΗΚΚ σε ασθενείς με HCV λοίμωξη» Evaluation of HCC risk in HCV patients «Εκτίμηση κινδφνου ανάπτυξης ΗΚΚ σε ασθενείς με HCV λοίμωξη» Evaluation of HCC risk in HCV patients Δημήτρησ Ν. αμωνάκησ Γαςτρεντερολογική κλινική Πανεπιςτημίου Κρήτησ Outline Epidemiology Risk factors

More information

Professor Vincent Soriano

Professor Vincent Soriano Five Nations Conference on HIV and Hepatitis in partnership with Professor Vincent Soriano Hospital Carlos III, Madrid, Spain Professor Vincent Soriano in partnership with Hospital Carlos III, Madrid,

More information

Intron A Hepatitis B. Intron A (interferon alfa-2b) Description

Intron A Hepatitis B. Intron A (interferon alfa-2b) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.01 Subject: Intron A Hepatitis B Page: 1 of 7 Last Review Date: November 30, 2018 Intron A Hepatitis

More information

Liver Cancer: Epidemiology and Health Disparities. Andrea Goldstein NP, MS, MPH Scientific Director Onyx Pharmaceuticals

Liver Cancer: Epidemiology and Health Disparities. Andrea Goldstein NP, MS, MPH Scientific Director Onyx Pharmaceuticals Liver Cancer: Epidemiology and Health Disparities Andrea Goldstein NP, MS, MPH Scientific Director Onyx Pharmaceuticals 1. Bosch FX, et al. Gastroenterology. 2004;127(5 suppl 1):S5-S16. 2. American Cancer

More information

Hepatitis B Epidemiology and Prevention in the Elimination Era John W. Ward, MD

Hepatitis B Epidemiology and Prevention in the Elimination Era John W. Ward, MD Hepatitis B Epidemiology and Prevention in the Elimination Era John W. Ward, MD Director, Program for Viral Hepatitis Elimination, Task Force for Global Health Senior Scientist, National Center for HIV/AIDS,

More information

Epatite B: fertilità, gravidanza ed allattamento, aspetti clinici e terapeutici. Ivana Maida

Epatite B: fertilità, gravidanza ed allattamento, aspetti clinici e terapeutici. Ivana Maida Epatite B: fertilità, gravidanza ed allattamento, aspetti clinici e terapeutici Ivana Maida Positivity for HBsAg was found in 0.5% of tested women In the 70s and 80s, Italy was one of the European countries

More information